Probiotic-based chemotherapy targeting immune-inhibitory receptors and cancer stem cells in chronic myelogenous leukemia (CML) and other metastatic cancers: A pharmaceutical mixture encompassing  Misoprostol, an FDA-approved EP4 agonist and abortion-promoting drug, and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as KIPRA, PTPN14, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets CML leukemic stem cells, confers protection against CML and prolongs survival, via up-regulation of its target gene, 31/December/2018, 7.04 pm